Skip to content
value.today

Hera Therapeutics Inc.

🇺🇸 Del Mar, California, USABiotechnologyFounded 2012
Total raised
$96 M
7 rounds on record
Latest round
$39 M
Apr 2023
First round on record
Feb 2013
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hera Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$39 MNo. 7$10 to $50 million

Hera Therapeutics Inc.: Raise no. 7, Apr 2023

Investors in this round

21 investors had bought by the notice of Oct 11, 2024: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$39 M of $53 M offered; $14 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elaine Chien · Executive Officer
  • Kristine Ball · Executive Officer, Director
  • Raju Gadiraju · Executive Officer
  • Sarah Walter · Executive Officer
  • Beni Rovinski · Director
  • Brian Goodman · Director
  • Clifford Samuel · Director
  • Florencia Segal · Director
  • Gail Maderis · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kristine Ball, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 11, 2024. Read the notice at the SEC.

equity, optionsSEC
Oct 2021$16 MNo. 6$10 to $50 million

Hera Therapeutics Inc.: Raise no. 6, Oct 2021

Investors in this round

20 investors had bought by the notice of Nov 3, 2021: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $31 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Maderis · Executive Officer, Director
  • Oranee Daniels · Executive Officer
  • Raju Gadiraju · Executive Officer
  • Sarah Walter · Executive Officer
  • Benjamin Rovinski · Director
  • Clifford Samuel · Director
  • David Kabakoff · Director
  • Jenny Yip · Director
  • Steven James · Director
  • Vinzenz Ploerer · Director
  • Wende Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gail Maderis, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 3, 2021. Read the notice at the SEC.

equitySEC
Jul 2018$15 MNo. 5$10 to $50 million

Hera Therapeutics Inc.: Raise no. 5, Jul 2018

Investors in this round

8 investors had bought by the notice of Jul 19, 2018: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Maderis · Executive Officer, Director
  • Oranee D. Daniels · Executive Officer
  • Raju D. Gadiraju, Ph.D. · Executive Officer
  • Sarah P. Walter · Executive Officer
  • Benjamin P. Rovinski · Director
  • David P. Kabakoff, Ph.D. · Director
  • Michael D. Cannon · Director
  • Steven P. James · Director
  • Ting P. Jia · Director
  • Vinzenz P. Ploerer · Director
  • Wende S. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D, newest notice filed Jul 19, 2018. Read the notice at the SEC.

equitySEC
Feb 2017$15 MNo. 4$10 to $50 million

Hera Therapeutics Inc.: Raise no. 4, Feb 2017

Investors in this round

15 investors had bought by the notice of Aug 28, 2017: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $26 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail Maderis · Executive Officer, Director
  • Oranee D. Daniels · Executive Officer
  • Raju P. Gadiraju, Ph.D. · Executive Officer
  • Sarah P. Walter · Executive Officer
  • Benjamin P. Rovinski · Director
  • David P. Kabakoff · Director
  • Michael D. Cannon · Director
  • Steven P. James · Director
  • Vinzenz P. Ploerer · Director
  • Wendee S. Hutton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan C. Mendelson, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Aug 28, 2017. Read the notice at the SEC.

equitySEC
May 2015$9 MNo. 3$2 to $10 million

Hera Therapeutics Inc.: Raise no. 3, May 2015

Investors in this round

26 investors had bought by the notice of Jun 11, 2015: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $16 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$18,288 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Sayward · Executive Officer
  • David Kabakoff · Director
  • Michael Cannon · Director
  • Steven James · Director
  • Wende Hutton · Director
  • William Respess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Sayward, Acting Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 11, 2015. Read the notice at the SEC.

equitySEC
Dec 2014$2 MNo. 2Under $2 million

Hera Therapeutics Inc.: Raise no. 2, Dec 2014

Investors in this round

19 investors had bought by the notice of Dec 23, 2014: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John W. Sayward · Executive Officer · Chief Operating Officer, Chief Financial Officer and Treasurer
  • Karl Y. Hostetler · Executive Officer, Director · President and Chief Executive Officer
  • Michael J. Sullivan · Executive Officer · Secretary
  • Michael D. Cannon · Director
  • William L. Respess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This filing covers the purchase and sale of Series B Preferred Stock, which includes the conversion of convertible promissory notes.”

Signed by John W. Sayward, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 23, 2014. Read the notice at the SEC.

equitySEC
Feb 2013$1 MNo. 1Under $2 million

Hera Therapeutics Inc.: Raise no. 1, Feb 2013

Investors in this round

18 investors had bought by the notice of Sep 5, 2013: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Karl Y Hostetler · Executive Officer, Director
  • Michael J Sullivan · Executive Officer
  • Michael D. Cannon · Director
  • William Y Respess · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael J. Sullivan, Corporate Secretary. Source: SEC Form D, newest notice filed Sep 5, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hera Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2024

That is all the official record says: Hera Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hera Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hera Therapeutics Inc.
NameRoleNamed in
Elaine ChienExecutive officerOct 2024
Kristine BallExecutive officerOct 2024
Raju GadirajuExecutive officerOct 2024
Sarah WalterExecutive officerOct 2024
Oranee DanielsExecutive officerMay 2023
Gail MaderisExecutive officerNov 2021
Oranee D. DanielsExecutive officerJul 2018
Raju D. Gadiraju, Ph.D.Executive officerJul 2018
Sarah P. WalterExecutive officerJul 2018
Raju P. Gadiraju, Ph.D.Executive officerAug 2017
Keith BleyExecutive officerApr 2017
John SaywardExecutive officerJun 2015
John W. SaywardChief Operating Officer, Chief Financial Officer and TreasurerDec 2014
Karl Y. HostetlerPresident and Chief Executive OfficerDec 2014
Michael J. SullivanSecretaryDec 2014
Karl Y HostetlerExecutive officerSep 2013
Michael J SullivanExecutive officerSep 2013
Beni RovinskiDirectorOct 2024
Brian GoodmanDirectorOct 2024
Clifford SamuelDirectorOct 2024
Florencia SegalDirectorOct 2024
Gail MaderisDirectorOct 2024
Kristine BallDirectorOct 2024
Wende HuttonDirectorOct 2024
Jenny YipDirectorMay 2023
Benjamin RovinskiDirectorNov 2021
David KabakoffDirectorNov 2021
Steven JamesDirectorNov 2021
Vinzenz PloererDirectorNov 2021
Benjamin P. RovinskiDirectorJul 2018
David P. Kabakoff, Ph.D.DirectorJul 2018
Michael D. CannonDirectorJul 2018
Steven P. JamesDirectorJul 2018
Ting P. JiaDirectorJul 2018
Vinzenz P. PloererDirectorJul 2018
Wende S. HuttonDirectorJul 2018
David P. KabakoffDirectorAug 2017
Wendee S. HuttonDirectorAug 2017
Michael CannonDirectorJun 2015
William RespessDirectorJun 2015